peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

rapid insulin

Insulin Lispro

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

In this source, Lyumjev is identified as an ultrarapid formulation of insulin lispro (a rapid-acting insulin analog). The primary pharmacologic mechanism of insulin (including insulin lispro–containing formulations) is regulation of glucose metabolism via increased peripheral glucose uptake and reduced hepatic glucose output, with additional effects on lipid and protein metabolism. In adults with type 1 diabetes performing exercise under CSII with a 100% BRR, URLi produced a smaller mean glucose decrease during exercise than insulin lispro. Hypoglycemia is identified as the most frequent adverse reaction for insulin therapies, including insulin lispro (HUMALOG).

Sources for this introduction: [1] [2] [3] [4]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Insulin lispro is a recombinant rapid-acting insulin analog (E. coli expression) with reversed B28/B29 residues versus human insulin (Lys at B28 and Pro at B29), with empirical formula C257H383N65O77S6 and molecular weight 5.808 kDa.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).Insulin lispro is a rapid-acting insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain ofEscherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6and a molecular weight of 5.808 kDa, both identical to that of human insulin.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulin lispro is a rapid-acting insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain ofEscherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6and a molecular weight of 5.808 kDa, both identical to that of human insulin.”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 11 DESCRIPTION

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Identity

In this source, Lyumjev is identified as an ultrarapid formulation of insulin lispro (a rapid-acting insulin analog).

Sources[6]pubmedMonomeric Insulin Analog and Stabilizing Excipient Enabled Ultrafast Insulin Formulation.Addition of clinically used absorption enhancers further accelerates its pharmacokinetic profile, producing a faster time-to-peak and reduced exposure relative to ultrarapid insulin lispro Lyumjev in this animal model.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Addition of clinically used absorption enhancers further accelerates its pharmacokinetic profile, producing a faster time-to-peak and reduced exposure relative to ultrarapid insulin lispro Lyumjev in this animal model.”

    Monomeric Insulin Analog and Stabilizing Excipient Enabled Ultrafast Insulin Formulation. · Abstract

    pubmed:42436611:a611af781d6e:a611af781d6e

How does it work?

Target, response, and disposition.

Mechanism

Insulin promotes intracellular potassium uptake; accordingly, the insulin lispro–containing Mix75/25 can shift potassium from extracellular to intracellular compartments, which may result in hypokalemia.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).All insulins, including Insulin Lispro Protamine and Insulin Lispro Mix75/25, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “All insulins, including Insulin Lispro Protamine and Insulin Lispro Mix75/25, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 5.6 Hypokalemia

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Mechanism

A recognized pharmacologic effect of insulin lispro is intracellular potassium shift, which can produce hypokalemia.

Sources[2]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro).All insulins, including Insulin Lispro, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “All insulins, including Insulin Lispro, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.”

    These highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro). · 5.6 Hypokalemia

    dailymed:2be14cbb-197a-4da8-82c8-2443594e7f6f:a1488baf60b2:a1488baf60b2

Mechanism

The primary pharmacologic mechanism of insulin (including insulin lispro–containing formulations) is regulation of glucose metabolism via increased peripheral glucose uptake and reduced hepatic glucose output, with additional effects on lipid and protein metabolism.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 12.1 Mechanism of Action

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Mechanism

As a class effect applicable to insulin analogs including insulin lispro, insulin lowers plasma glucose by increasing peripheral glucose uptake (skeletal muscle and adipose tissue) and suppressing hepatic glucose output.

Sources[1]dailymedThese highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Source records
2
Regulatory records
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.”

    These highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017 · 12.1 Mechanism of Action

    dailymed:0691def8-4a7b-4de3-866f-a280989f47f1:94c9f52ac4b7:94c9f52ac4b7
  2. supports · Source-backed record
    “Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 12.1 Mechanism of Action

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Pharmacokinetics

Compared with regular human insulin, subcutaneous insulin lispro shows faster onset and shorter duration of pharmacodynamic activity.

Sources[2]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro).Studies in normal volunteers and patients with diabetes demonstrated that Insulin Lispro has a more rapid onset of action and a shorter duration of activity than regular human insulin when given subcutaneously.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Studies in normal volunteers and patients with diabetes demonstrated that Insulin Lispro has a more rapid onset of action and a shorter duration of activity than regular human insulin when given subcutaneously.”

    These highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro). · 12.2 Pharmacodynamics

    dailymed:2be14cbb-197a-4da8-82c8-2443594e7f6f:a1488baf60b2:a1488baf60b2

What has been studied?

What the evidence says.

Comparative evidence

In adults with type 1 diabetes performing exercise under CSII with a 100% BRR, URLi produced a smaller mean glucose decrease during exercise than insulin lispro.

Sources[5]pubmedUltra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion.URLi significantly attenuated the reduction in glucose level compared with lispro during both the 50% BRR (-26.8 ± 37 vs. -39.0 ± 39 mg/dL; P < 0.05)[5]pubmedUltra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion.and the 100% BRR (-46.9 ± 32 vs. -60.5 ± 39 mg/dL; P < 0.01).
Reported result
-26.8 ± 37 vs. -39.0 ± 39 mg/dL; P < 0.05
Source records
2
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “URLi significantly attenuated the reduction in glucose level compared with lispro during both the 50% BRR (-26.8 ± 37 vs. -39.0 ± 39 mg/dL; P < 0.05)”

    Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion. · RESULTS

    pubmed:41885780:1c1e7299f8e8:1c1e7299f8e8
  2. supports · Source-backed record
    “and the 100% BRR (-46.9 ± 32 vs. -60.5 ± 39 mg/dL; P < 0.01).”

    Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion. · RESULTS

    pubmed:41885780:1c1e7299f8e8:1c1e7299f8e8

Study findings

Insulin lispro (HUMALOG) is indicated for improving glycemic control in people with diabetes mellitus, including both adult and pediatric patients.

Sources[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 1 INDICATIONS AND USAGE

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Risks and interactions

Risks, organized for scanning.

Contraindications

The insulin lispro–containing premix is contraindicated when a patient is experiencing hypoglycemia, reflecting risk of worsening low glucose.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).Insulin Lispro Protamine and Insulin Lispro Mix75/25 is contraindicated:during episodes of hypoglycemia[see Warnings and Precautions (5.3)]
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulin Lispro Protamine and Insulin Lispro Mix75/25 is contraindicated:during episodes of hypoglycemia[see Warnings and Precautions (5.3)]”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 4 CONTRAINDICATIONS

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Contraindications

Insulin lispro (HUMALOG) is contraindicated when a patient is experiencing hypoglycemia, because administering insulin in this setting can worsen low blood glucose.

Sources[1]dailymedThese highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017ADMELOG is contraindicated:during episodes of hypoglycemia[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996HUMALOG is contraindicated:during episodes of hypoglycemia[see Warnings and Precautions (5.3)].
Source records
2
Regulatory records
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “ADMELOG is contraindicated:during episodes of hypoglycemia”

    These highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017 · 4 CONTRAINDICATIONS

    dailymed:0691def8-4a7b-4de3-866f-a280989f47f1:94c9f52ac4b7:94c9f52ac4b7
  2. supports · Source-backed record
    “HUMALOG is contraindicated:during episodes of hypoglycemia[see Warnings and Precautions (5.3)].”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 4 CONTRAINDICATIONS

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Contraindications

Contraindications include active hypoglycemia and hypersensitivity to insulin lispro or formulation excipients.

Sources[2]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro).Insulin Lispro is contraindicated:during episodes of hypoglycemia[see Warnings and Precautions (5.3)].in patients who are hypersensitive to Insulin Lispro or to any of the excipients in Insulin Lispro[see Warnings and Precautions (5.5)].
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulin Lispro is contraindicated:during episodes of hypoglycemia[see Warnings and Precautions (5.3)].in patients who are hypersensitive to Insulin Lispro or to any of the excipients in Insulin Lispro[see Warnings and Precautions (5.5)].”

    These highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro). · 4 CONTRAINDICATIONS

    dailymed:2be14cbb-197a-4da8-82c8-2443594e7f6f:a1488baf60b2:a1488baf60b2

Interactions

When mixing insulins for subcutaneous injection, HUMALOG U-100 is permitted to be mixed only with NPH insulin preparations; HUMALOG U-100 should be drawn up first and administered immediately after mixing to preserve intended pharmacologic behavior.

Sources[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996HUMALOG U-100 may be mixed with NPH insulin preparationsONLY.If HUMALOG U-100 is mixed with NPH insulin, HUMALOG U-100 should be drawn into the syringe first. Injection should occur immediately after mixing.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “HUMALOG U-100 may be mixed with NPH insulin preparationsONLY.If HUMALOG U-100 is mixed with NPH insulin, HUMALOG U-100 should be drawn into the syringe first. Injection should occur immediately after mixing.”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 2.5 Instructions for Mixing with Other Insulins

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Safety findings

Insulin Lispro shares class risk: hypoglycemia is most common, and severe episodes may include seizures and can be life-threatening or fatal.

Sources[2]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro).Hypoglycemia is the most common adverse reaction associated with insulins, including Insulin Lispro. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Hypoglycemia is the most common adverse reaction associated with insulins, including Insulin Lispro. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.”

    These highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro). · 5.3 Hypoglycemia

    dailymed:2be14cbb-197a-4da8-82c8-2443594e7f6f:a1488baf60b2:a1488baf60b2

Safety findings

Across insulin therapies, hypoglycemia is the most frequent adverse reaction; this includes insulin lispro–containing Insulin Lispro Protamine and Insulin Lispro Mix75/25.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).Hypoglycemia is the most common adverse reaction associated with all insulins, including Insulin Lispro Protamine and Insulin Lispro Mix75/25.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Hypoglycemia is the most common adverse reaction associated with all insulins, including Insulin Lispro Protamine and Insulin Lispro Mix75/25.”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 5.3 Hypoglycemia

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Safety findings

To reduce risk of blood-borne pathogen transmission, the insulin lispro–containing Mix75/25 KwikPen is designated for single-patient use and should not be shared even with needle changes.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).Insulin Lispro Protamine and Insulin Lispro Mix75/25 KwikPens must never be shared between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulin Lispro Protamine and Insulin Lispro Mix75/25 KwikPens must never be shared between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 5.1 Never Share an Insulin Lispro Protamine and Insulin Lispro Mix75/25 KwikPen Between Patients

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Safety findings

To avoid dosing errors, HUMALOG U-200 should not be withdrawn from the prefilled pen and administered by syringe.

Sources[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996Do NOT transfer HUMALOG U-200 from the prefilled pen to a syringe for administration[see Warnings and Precautions (5.4)].
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Do NOT transfer HUMALOG U-200 from the prefilled pen to a syringe for administration[see Warnings and Precautions (5.4)].”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 2.1 Important Administration Instructions

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Safety findings

Hypoglycemia is identified as the most frequent adverse reaction for insulin therapies, including insulin lispro (HUMALOG).

Sources[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996Hypoglycemia is the most common adverse reaction associated with insulins, including HUMALOG.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Hypoglycemia is the most common adverse reaction associated with insulins, including HUMALOG.”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 5.3 Hypoglycemia

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Safety findings

Insulin therapy, including insulin lispro (HUMALOG), promotes intracellular potassium uptake (a transcellular shift), which can produce hypokalemia.

Sources[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996All insulins, including HUMALOG, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “All insulins, including HUMALOG, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 5.6 Hypokalemia

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Products and regulatory status

Same ingredient. Different records.

Regulatory status

The labeled indication for the insulin lispro–containing premix Insulin Lispro Protamine and Insulin Lispro Mix75/25 is improvement of glycemic control in adults with diabetes mellitus.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).Insulin Lispro Protamine and Insulin Lispro Mix75/25 is indicated to improve glycemic control in adults with diabetes mellitus.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulin Lispro Protamine and Insulin Lispro Mix75/25 is indicated to improve glycemic control in adults with diabetes mellitus.”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 1 INDICATIONS AND USAGE

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Regulatory status

Insulin Lispro has an approved indication for improving glycemic control in both adult and pediatric patients with diabetes mellitus.

Sources[1]dailymedThese highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.[2]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro).Insulin Lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Source records
2
Regulatory records
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.”

    These highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017 · 1 INDICATIONS AND USAGE

    dailymed:0691def8-4a7b-4de3-866f-a280989f47f1:94c9f52ac4b7:94c9f52ac4b7
  2. supports · Source-backed record
    “Insulin Lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.”

    These highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro). · 1 INDICATIONS AND USAGE

    dailymed:2be14cbb-197a-4da8-82c8-2443594e7f6f:a1488baf60b2:a1488baf60b2

Administration context

The practical clinical context.

Administration

For dose dialing that depends on audible clicks, Insulin Lispro prefilled pens require caution in patients with visual impairment.

Sources[2]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro).Use Insulin Lispro prefilled pens with caution in patients with visual impairment that may rely on audible clicks to dial their dose.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Use Insulin Lispro prefilled pens with caution in patients with visual impairment that may rely on audible clicks to dial their dose.”

    These highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro). · 2.1 Important Administration Instructions

    dailymed:2be14cbb-197a-4da8-82c8-2443594e7f6f:a1488baf60b2:a1488baf60b2

Administration

For subcutaneous injection, Insulin Lispro is compatible for mixing only with NPH preparations; proper technique is to draw Insulin Lispro first and administer immediately after mixing.

Sources[2]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro).Insulin Lispro may be mixed with NPH insulin preparationsONLY.If Insulin Lispro is mixed with NPH insulin, Insulin Lispro should be drawn into the syringe first. Injection should occur immediately after mixing.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulin Lispro may be mixed with NPH insulin preparationsONLY.If Insulin Lispro is mixed with NPH insulin, Insulin Lispro should be drawn into the syringe first. Injection should occur immediately after mixing.”

    These highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro). · 2.5 Instructions for Mixing with Other Insulins

    dailymed:2be14cbb-197a-4da8-82c8-2443594e7f6f:a1488baf60b2:a1488baf60b2

Administration

For continuous subcutaneous insulin infusion (CSII), insulin lispro U-100 (HUMALOG U-100) should not be mixed with other insulin products in the pump system.

Sources[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996Do NOT mix HUMALOG U-100 with other insulins when using a continuous subcutaneous infusion pump.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Do NOT mix HUMALOG U-100 with other insulins when using a continuous subcutaneous infusion pump.”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 2.1 Important Administration Instructions

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Administration

For this insulin lispro–containing premix, recommended administration timing is subcutaneous injection within 15 minutes prior to a meal.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).Inject Insulin Lispro Protamine and Insulin Lispro Mix75/25 subcutaneously within 15 minutes before a meal.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Inject Insulin Lispro Protamine and Insulin Lispro Mix75/25 subcutaneously within 15 minutes before a meal.”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 2.2 Dosage Recommendations

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Dose records

Typical dosing frequency for this insulin lispro–containing premix is twice daily, with each injection intended to provide coverage for 2 meals or for a meal and a snack.

Sources[4]dailymedThese highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro).Insulin Lispro Protamine and Insulin Lispro Mix75/25 is typically dosed twice-daily (with each dose intended to cover 2 meals or a meal and a snack).
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Insulin Lispro Protamine and Insulin Lispro Mix75/25 is typically dosed twice-daily (with each dose intended to cover 2 meals or a meal and a snack).”

    These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). · 2.2 Dosage Recommendations

    dailymed:e49f701d-c19f-4cb2-b63f-01a917b33abc:262b4939161b:262b4939161b

Dose records

Dosage forms/strength: ADMELOG (insulin lispro) injection is a clear, colorless solution at 100 units/mL (U-100), packaged as 10 mL multiple-dose vials, 3 mL multiple-dose vials, and 3 mL single-patient-use SoloStar prefilled pens.

Sources[1]dailymedThese highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017Injection: 100 units/mL (U-100) is a clear and colorless solution available as:10 mL multiple-dose vials3 mL multiple-dose vials3 mL single-patient-use SoloStar prefilled pens
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Injection: 100 units/mL (U-100) is a clear and colorless solution available as:10 mL multiple-dose vials3 mL multiple-dose vials3 mL single-patient-use SoloStar prefilled pens”

    These highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017 · 3 DOSAGE FORMS AND STRENGTHS

    dailymed:0691def8-4a7b-4de3-866f-a280989f47f1:94c9f52ac4b7:94c9f52ac4b7

Dose records

Dose conversion guidance: switching from another insulin lispro product to ADMELOG is recommended on a unit-to-unit basis (same dose).

Sources[1]dailymedThese highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017When switching from another insulin lispro product to ADMELOG, the dose of ADMELOG should be the same as the other insulin lispro product
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “When switching from another insulin lispro product to ADMELOG, the dose of ADMELOG should be the same as the other insulin lispro product”

    These highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017 · 2.3 Dosage Recommendations

    dailymed:0691def8-4a7b-4de3-866f-a280989f47f1:94c9f52ac4b7:94c9f52ac4b7

Dose records

HUMALOG U-100 and U-200 prefilled pens are designed to display the actual insulin units to be delivered in the dose window, so manual unit conversion is not required.

Sources[3]dailymedThese highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996Do NOT perform dose conversion when using any HUMALOG U-100 or U-200 prefilled pens. The dose window shows the number of insulin units to be delivered and no conversion is needed.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Do NOT perform dose conversion when using any HUMALOG U-100 or U-200 prefilled pens. The dose window shows the number of insulin units to be delivered and no conversion is needed.”

    These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 · 2.1 Important Administration Instructions

    dailymed:c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f:c3a574448150:c3a574448150

Research status + gaps

What still needs better answers?

  • 57 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (26), assurance_score_below_0.72 (28), current_regulatory_source_required (17), extraction_ambiguity (37), high_risk_requires_regulatory_or_two_independent_sources (29), no_direct_support (54)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. These highlights do not include all the information needed to use ADMELOG safely and effectively. See full prescribing information for ADMELOG®.ADMELOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2017 ↗

    dailymed · published 2025-06-04 · retrieved 2026-09-04T19:34:14Z

  2. These highlights do not include all the information needed to use INSULIN LISPRO safely and effectively. See full prescribing information for INSULIN LISPRO.INSULIN LISPRO injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996This product is HUMALOG® (insulin lispro). ↗

    dailymed · published 2024-05-31 · retrieved 2026-09-04T19:34:15Z

  3. These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.HUMALOG (insulin lispro) injection, for subcutaneous or intravenous useInitial U.S. Approval: 1996 ↗

    dailymed · published 2026-06-16 · retrieved 2026-09-04T19:34:16Z

  4. These highlights do not include all the information needed to use INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25 safely and effectively. See full prescribing information for INSULIN LISPRO PROTAMINE AND INSULIN LISPRO MIX75/25.INSULIN LISPRO PROTAMINE AND INSULIN LISPRO injectable suspension Mix75/25, for subcutaneous useInitial U.S. Approval: 1999This product is HUMALOG®Mix75/25™ (insulin lispro protamine and insulin lispro). ↗

    dailymed · published 2024-08-06 · retrieved 2026-09-04T19:34:14Z

  5. Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion. ↗

    pubmed · published 2026-07-01 · retrieved 2026-08-27T11:48:55Z

  6. Monomeric Insulin Analog and Stabilizing Excipient Enabled Ultrafast Insulin Formulation. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-27T11:48:55Z

Publication history and provenance

Version 5 · Automated assessment · 2026-09-04T19:34:16Z

63486e1774d0985afcecbca86e0e53e1826e36f0b8974cc931a7c7719c3d4f1f